How did Danaher perform in Q4 2024 compared with a year earlier?

Q4 2024 sales rose 2.0% to $6.5 billion, and non-GAAP core revenue grew 1.0%. GAAP diluted EPS was $1.49, versus $1.50 a year earlier, and adjusted diluted EPS rose to $2.14 from $2.09. Operating profit increased to $1.4 billion from $1.3 billion, and operating margin reached 21.8% versus 20.9%.

Why did full-year 2024 adjusted EPS decline even though free cash flow improved?

Adjusted diluted EPS fell to $7.48 from $7.58 as core revenue declined 1.5%, interest income dropped sharply to $117 million from $303 million, and the operating margin compressed in 2024. Free cash flow rose to $5.3 billion, but that growth reflects cash generation rather than earnings, and the EPS decline was driven mainly by lower operating profit and reduced interest income.

What does the 2025 guidance imply for investors?

Management expects Q1 2025 non-GAAP core revenue to decline low-single digits year-over-year, with full-year 2025 core revenue growing about 3%. The weak first quarter implies a back-half-weighted recovery, and investors will want evidence that growth returns as expected. The guidance excludes currency, acquisitions and divestitures, so reported GAAP revenue may differ.

How much did Danaher return to shareholders and how did it affect the balance sheet?

Danaher repurchased $6.0 billion of common stock and paid $768 million in dividends in 2024. Cash fell to $2.1 billion from $5.9 billion, and total debt declined to about $16.0 billion from $18.4 billion, driven by repayments of $1.7 billion. Total stockholders' equity fell to $49.6 billion from $53.5 billion, largely because of treasury stock purchases.

Which segments drove performance in 2024?

Diagnostics was the strongest segment, with core sales up 3.0% and operating profit rising to $2.6 billion from $2.4 billion, and an operating margin of 26.8%. Biotechnology had core sales down 4.5% and operating profit fell to $1.7 billion from $1.9 billion. Life Sciences was weak, with core sales down 2.0% and operating margin falling to 12.0% from 16.9%.

DHR 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed January 29, 2025. Cited figures are marked; the original filing is the authoritative source.

Danaher reported fourth-quarter and full-year 2024 results on January 29, 2025, with all figures reflecting continuing operations.

For Q4 2024, revenue rose 2.0% year-over-year to $6.5 billion^a, with non-GAAP core revenue up 1.0%. GAAP diluted EPS was $1.49 and non-GAAP adjusted diluted EPS was $2.14, versus $2.09 a year earlier. Operating cash flow was $2.0 billion and free cash flow was $1.5 billion, up roughly 29.5% year-over-year.

Management highlighted better-than-anticipated core revenue across all three segments and operating margin expansion. For full-year 2024, sales were flat at $23.9 billion^b, but non-GAAP core revenue declined 1.5%. GAAP diluted EPS was $5.29 and adjusted diluted EPS was $7.48, down from $7.58.

Operating profit fell to $4.9 billion^c from $5.2 billion, though the operating margin was 20.4% versus 21.8%. Free cash flow was $5.3 billion, up about 3.5%. The balance sheet shows cash falling to $2.1 billion from $5.9 billion, mainly because of $6.0 billion in share repurchases, and total debt declining to about $16.0 billion.

Management pointed to a more focused life sciences and diagnostics portfolio as the basis for higher long-term growth and margins. Guidance is mixed.

Management expects first-quarter 2025 core revenue to decline low-single digits year-over-year, and full-year 2025 core revenue to grow about 3%^d. Investors should weigh the strong cash generation and buybacks against a soft start to 2025, the Biotechnology and Life Sciences core declines in 2024, and the continued goodwill and intangible asset amortization burden.

02—Key points

Key Highlights

Q4 2024 revenue grew 2.0% to $6.5B, with non-GAAP core revenue up 1.0%; all three segments beat expectations per management.
FY 2024 sales were flat at $23.9B, while non-GAAP core revenue declined 1.5%, led by a 4.5% core decline in Biotechnology.
Adjusted diluted EPS was $7.48 for FY 2024 (vs. $7.58 in 2023) and $2.14 for Q4 2024 (vs. $2.09); GAAP diluted EPS was $5.29 for the year.
Free cash flow reached $5.3B for FY 2024 (+3.5%) and $1.5B in Q4 (+29.5%), supported by operating cash flow of $6.7B for the year.
FY 2024 operating margin contracted to 20.4% from 21.8%, with Life Sciences margin falling to 12.0% from 16.9%.
Danaher repurchased $6.0B of common stock in 2024, cutting cash to $2.1B from $5.9B and reducing shares outstanding to 719.1M from 739.2M.
2025 guidance calls for Q1 core revenue to decline low-single digits and full-year core revenue to grow approximately 3%.

03—Questions

Frequently Asked Questions

How did Danaher perform in Q4 2024 compared with a year earlier?
Q4 2024 sales rose 2.0% to $6.5 billion, and non-GAAP core revenue grew 1.0%. GAAP diluted EPS was $1.49, versus $1.50 a year earlier, and adjusted diluted EPS rose to $2.14 from $2.09. Operating profit increased to $1.4 billion from $1.3 billion, and operating margin reached 21.8% versus 20.9%.
Why did full-year 2024 adjusted EPS decline even though free cash flow improved?
Adjusted diluted EPS fell to $7.48 from $7.58 as core revenue declined 1.5%, interest income dropped sharply to $117 million from $303 million, and the operating margin compressed in 2024. Free cash flow rose to $5.3 billion, but that growth reflects cash generation rather than earnings, and the EPS decline was driven mainly by lower operating profit and reduced interest income.
What does the 2025 guidance imply for investors?
Management expects Q1 2025 non-GAAP core revenue to decline low-single digits year-over-year, with full-year 2025 core revenue growing about 3%. The weak first quarter implies a back-half-weighted recovery, and investors will want evidence that growth returns as expected. The guidance excludes currency, acquisitions and divestitures, so reported GAAP revenue may differ.
How much did Danaher return to shareholders and how did it affect the balance sheet?
Danaher repurchased $6.0 billion of common stock and paid $768 million in dividends in 2024. Cash fell to $2.1 billion from $5.9 billion, and total debt declined to about $16.0 billion from $18.4 billion, driven by repayments of $1.7 billion. Total stockholders' equity fell to $49.6 billion from $53.5 billion, largely because of treasury stock purchases.
Which segments drove performance in 2024?
Diagnostics was the strongest segment, with core sales up 3.0% and operating profit rising to $2.6 billion from $2.4 billion, and an operating margin of 26.8%. Biotechnology had core sales down 4.5% and operating profit fell to $1.7 billion from $1.9 billion. Life Sciences was weak, with core sales down 2.0% and operating margin falling to 12.0% from 16.9%.

04—Continue

← View all 8-K filings